- Home
- MACI vs XOMA Comparison
MACI vs XOMA Comparison
Compare MACI & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MACI
- XOMA
- Stock Information
- Founded
- MACI 2024
- XOMA 1981
- Country
- MACI United States
- XOMA United States
- Employees
- MACI N/A
- XOMA N/A
- Industry
- MACI
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- MACI
- XOMA Health Care
- Exchange
- MACI NYSE
- XOMA Nasdaq
- Market Cap
- MACI 221.6M
- XOMA 250.1M
- IPO Year
- MACI 2024
- XOMA N/A
- Fundamental
- Price
- MACI $10.28
- XOMA $21.18
- Analyst Decision
- MACI
- XOMA Strong Buy
- Analyst Count
- MACI 0
- XOMA 3
- Target Price
- MACI N/A
- XOMA $59.67
- AVG Volume (30 Days)
- MACI 15.0K
- XOMA 26.2K
- Earning Date
- MACI 01-01-0001
- XOMA 05-08-2025
- Dividend Yield
- MACI N/A
- XOMA N/A
- EPS Growth
- MACI N/A
- XOMA N/A
- EPS
- MACI N/A
- XOMA N/A
- Revenue
- MACI N/A
- XOMA $28,487,000.00
- Revenue This Year
- MACI N/A
- XOMA $14.22
- Revenue Next Year
- MACI N/A
- XOMA $34.01
- P/E Ratio
- MACI $44.00
- XOMA N/A
- Revenue Growth
- MACI N/A
- XOMA 498.72
- 52 Week Low
- MACI $9.95
- XOMA $18.35
- 52 Week High
- MACI $10.35
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- MACI N/A
- XOMA 54.26
- Support Level
- MACI N/A
- XOMA $20.00
- Resistance Level
- MACI N/A
- XOMA $21.55
- Average True Range (ATR)
- MACI 0.00
- XOMA 1.20
- MACD
- MACI 0.00
- XOMA 0.29
- Stochastic Oscillator
- MACI 0.00
- XOMA 79.27
About MACI MELAR ACQUISITION CORP. I
Melar Acquisition Corp I is a blank check company.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.